CN103637179A - 一种降血糖、降血脂和改善脂肪肝的食物组合物 - Google Patents
一种降血糖、降血脂和改善脂肪肝的食物组合物 Download PDFInfo
- Publication number
- CN103637179A CN103637179A CN201310469837.6A CN201310469837A CN103637179A CN 103637179 A CN103637179 A CN 103637179A CN 201310469837 A CN201310469837 A CN 201310469837A CN 103637179 A CN103637179 A CN 103637179A
- Authority
- CN
- China
- Prior art keywords
- food composition
- parts
- fatty liver
- blood
- hypoglycemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 71
- 239000008280 blood Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 235000013305 food Nutrition 0.000 title claims abstract description 29
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 23
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 23
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 22
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 22
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 12
- 241001598107 Imperata Species 0.000 claims abstract description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 235000021013 raspberries Nutrition 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 16
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 13
- 241001092040 Crataegus Species 0.000 claims description 11
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 11
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 11
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 11
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 11
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 11
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 11
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 11
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 11
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 11
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 11
- 244000241838 Lycium barbarum Species 0.000 claims description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 10
- 240000003582 Platycodon grandiflorus Species 0.000 claims description 9
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 9
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 244000025254 Cannabis sativa Species 0.000 abstract description 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000002960 lipid emulsion Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003934 vacuole Anatomy 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FXLJDRXREUZRIC-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO FXLJDRXREUZRIC-BAOOBMCLSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- -1 triterpene glucoside Chemical class 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000019137 high fructose diet Nutrition 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种降血糖、降血脂和改善脂肪肝的组合食物,属于功能食品领域。具体地说是一种降血糖、降血脂及改善脂肪肝的组合食物及其制备方法。所述的组合物中含有葛根3-6份、黄精3-6份、覆盆子3-6份、枸杞2-4份、山楂2-4份、桔梗1-3份、白茅根1-2份。本发明经对糖调节受损小鼠实验研究发现,该组合物能够显著提高糖耐量、增加胰岛素敏感性、降低空腹血糖、降低血脂、改善脂肪肝。本发明组合物可用于制备辅助降血糖、降血脂和改善脂肪肝的保健食品,具有无毒副作用、安全性和经济性高等显著优点。
Description
技术领域
本发明属于功能食品技术领域,具体涉及一种降血糖、降血脂和改善脂肪肝的功能食品组合物配方和生产方法。
背景技术
随着人们生活水平的提高,由于人们饮食结构的改变、日趋紧张的生活节奏以及少动多坐的生活方式等诸多因素的影响,全球糖尿病发病率逐年增高,已成为导致全球人口死亡的第四大疾病。据最新数据统计,目前中国糖尿病人群大约为1.13亿,糖尿病前期为4.93亿。糖调节受损(IGR)是糖代谢介于正常与2型糖尿病之间的过渡状态,是糖尿病的前期阶段。对IGR进行有效的干预可防止和延缓糖尿病的发生、发展,延缓微血管和大血管的并发症,从而将明显降低人群的死亡率。糖尿病归属于中医学“消渴病”范畴,而IGR则相应为“消渴病”的前期或早期阶段。因此针对气阴两虚,痰瘀内阻,进行标本同治,对扭转病势,改善胰岛素抵抗非常关键。IGR人群中,并发症如高血脂和脂肪肝病变也普遍存在。肝脏脂肪沉积后易出现糖吸收异常,并导致更加严重的IGR。因此同时调节高血脂和脂肪肝,对于延缓IGR发展为糖尿病同样具有重要意义。
目前普遍认为,糖调节受损阶段虽然已出现糖代谢轻度紊乱,但仍不能认为是一种疾病,而是一种亚健康状态,所以如果采用治疗糖尿病的方法如服用西药等加以调控往往会矫枉过正,造成低血糖症、胃肠道反应等副作用。根据传统中医理论药食同源理论,本发明结合中医药学理论,选择功能性食品进行合理配比,组成专利配方。配方食物组合物为药食同源食物,适于每日食用,使糖调节受损患者得到调节血糖和脂肪代谢、保护和提高脏器功能、改善身体机能等多重益处。
发明内容
本发明中针对现有技术中存在的不足,提出一种降低血糖、降血脂及改善脂肪肝的食物组合物,效果显著,且无副作用。
本发明解决其技术问题所采用的技术方案是:该一种降低血糖、降血脂及改善脂肪肝的食物组合物,其特征在于所述食物组合物中有效原料组成及其重量配比为:葛根3-6份、黄精3-6份、覆盆子3-6份、枸杞2-4份、山楂2-4份、桔梗1-3份、白茅根1-2份。
优选的,制成该食物组合物有效成分的原料组成及其重量配比为:葛根4份、黄精4份、覆盆子4份、枸杞3份、山楂3份、桔梗2份、白茅根1份。
配比时优选将所述的葛根、黄精和覆盆子按等量加入。
配比时优选将所述的枸杞和山楂按等量加入。
本发明还提供了该食物组合物有效成分的制备工艺,具体采用如下步骤:
步骤A:按重量比精选葛根、黄精、覆盆子、枸杞、山楂、桔梗、白茅根,机械粉碎,过60目筛,获得药材颗粒;
步骤B:加入药材颗粒重量8倍的70%的乙醇,50℃下超声波提取30min,提取三次,过滤,合并提取液;
步骤C:减压回收溶剂,温度低于55℃,得醇提膏状物,进一步干燥为粉状物质。
上述食物组合物提取物粉状物可制成粉状或颗粒状的营养粉或片剂或胶囊剂。
葛根,味甘、辛,性凉,归脾、胃经,具有生津止渴,升阳止泻之功;早在《神农本草经》中就有“葛根气味甘平无毒,主消渴”的记载;《圣济总录》中的葛根汁为治疗消渴的单方,用一味葛根清热解毒,生津止渴,润燥除烦,健脾升清,以助津液化源与输布。葛根的主要成分葛根素,具有抑制体内自由基、降血糖和改善微血管病变等效果。
黄精,味甘、性平,归脾、肺、肾经。具有补脾润肺、益气养阴之功效,用于滋补强身和治疗肾虚、肺虚以及脾胃虚弱之症。现代药理学研究发现,黄精中含有多种甾体皂甙类成 分和黄酮类物质,有利于增强机体免疫力,同时具有降血脂、降血糖和延缓衰老等作用。
覆盆子:性温,味甘酸,平。归肾、膀胱经。含有机酸、糖类及维生素C,补肝肾,缩小便,助阳,固精,明目,虚劳。
枸杞子,味甘、性平,有补肾、滋阴、养肝、明目、益气等功效。现代研究发现枸杞子具有抗癌、抗脂肪肝、降血压和促进机体调节免疫功能等作用。常用于改善糖尿病、肝病和老年保健。
山楂酸甘,功擅健脾开胃,活血散瘀、化痰行气,尤善化油腻肉食积滞。山楂能防治心血管疾病,具有软化血管、降血压、降血脂、改善血液循环作用。
桔梗味辛苦,镇静、镇痛、解热,祛痰,疗喉咽痛,利五脏肠胃,有扩张血管、减慢心率,降血糖和降血脂,利尿消肿、抗溃疡、抗过敏、抗肿瘤等功效。主要含多种三萜甙类如熊果酸、齐墩果酸等,黄酮类如芦丁、大樨草素等化合物。现代药理研究表明植物中皂甙类、黄酮类等成分具有抗炎的活性。
白茅根:性寒,味甘。甘寒清热,生津利尿。常以单味或复方治疗小便不利、血尿及乳糜尿、水肿和肝炎等。《本经》有“主劳伤虚赢、补中益气、除淤血、血闭寒热、利小便”的记载。
根据动物实验结果可见,本发明的食物组合物经长期给药后,在减低餐后血糖和空腹血糖,改善高血脂症和脂肪肝的效果显著。
附图说明
附图是小鼠肝组织脂肪变性病理学改变图(油红O染色,×200),其中,NC:正常对照组(上左);MC:模型对照组(上中);PC:阳性对照组(上右);AMF:配方醇提物中剂量组(下左);AHF:配方醇提物高剂量组(下右);→,红染脂滴。
具体实施方式
以下通过具体实施例对本发明进行详细说明。下述实施例,仅为本发明的代表举例而已,不应理解为本发明实施的限定范围。凡是对本发明配方、生产工艺步骤和条件的简单替换或变化,均属于本发明的保护范围。
实施例1
取葛根200g、黄精200g、覆盆子200g、枸杞150g、山楂150g,桔梗100g,白茅根50g,机械粉碎,过60目筛。加入药材颗粒重量8倍的70%乙醇,50℃下超声波提取30min,提取三次,合并提取液,减压回收溶剂至合适体积,得醇提膏状物,干燥,制得营养粉剂。
实施例2
取葛根300g、黄精300g、覆盆子300g、枸杞200g、山楂200g,桔梗120g,白茅根60g,机械粉碎,过60目筛。加入药材颗粒重量8倍的70%乙醇,50℃下超声波提取30min,提取三次,合并提取液,减压回收溶剂至合适体积,得醇提物稠膏,加入适量糊精,混匀,制成颗粒,干燥,压制成片,制得片剂。
实施例3
将上述实施例1制备所得的食品组合进行如下药效学实验:
将本发明实施例1制备所得的食品组合醇提取物干燥粉末对高脂高果糖饮食诱导的糖调节受损小鼠模型进行降血糖、降血脂及改善脂肪肝作用实验:
1.实验材料与方法
实验动物:SPF级ICR小鼠,20-22g,雄性,北京维通利华实验动物技术有限公司提供,合格证号:SCXK(京)2007-0001。小鼠饲料成分:碳水化合物64%,蛋白质21%,脂肪4%,纤维5%,购于北京动物实验中心。小鼠饲养于中国农业大学食品科学与营养工程学院动物实验中心(SPF级)。室内通风条件良好,正常昼夜变化,相对湿度为55±5%,室温:23±2℃。
实验方法:小鼠适应性喂养7天后,将50只小鼠随机分为5组,每组10只,作如下分组: 正常对照组(NC),灌胃7%吐温-80溶液;模型对照组(MC),灌胃脂肪乳的同时以15%果糖水作为唯一水源;二甲双胍阳性对照组(PC);本发明实施例1制备所得的食品组合物醇提物中剂量组(AMF)和高剂量组(AHF)。各组均食用常规饲料,NC组饮用纯净水;除NC组外,其余各组均灌胃脂肪乳,以15%果糖水作为唯一水源。脂肪乳制备方法:猪油50g,胆固醇1.5g,猪胆盐0.3g,吐温-807mL,加水定容至100mL,配成脂肪乳,-20℃保存。
每日灌胃剂量(中)=食用量÷体重(以60kg计)×动物体重×20倍公式(1)
每日灌胃剂量(高)=食用量÷体重(以60kg计)×动物体重×30倍公式(2)
配方的醇提取物的灌胃量以公式(1)和(2)进行计算,然后用蒸馏水稀释成小鼠的适应灌胃体积(0.2mL/10g b.w),阳性对照组灌胃0.5g/kg b.w.二甲双胍。
2.测定及观察指标
适应饲养结束后,对各组按照以上分组进行干预实验,连续灌胃10周,每三天称重1次,随体重调整给药量。试验第9周末测定糖耐量,试验第10周末测定胰岛素耐量。实验结束时,动物给药后禁食13h,不限饮水,摘眼球采血,测定TC、TG、HDL-C、LDL-C和FFA含量。解剖小鼠,取其肝称重量后,其中一部分肝进行组织切片观察。
2.1.血糖的测定
小鼠禁食(不禁水)13h,割尾静脉采血,用强生血糖仪测定小鼠血糖,直接读取数据。
2.2.口服糖耐量试验(OGTT)
小鼠禁食(不禁水)13h,各组小鼠经口给予2.0g/kg b.w.葡萄糖溶液。在随后120min内,分别在0min、30min、60min、120min割尾静脉采血,血糖仪测定血糖。糖耐量曲线下面积(AUC)采用梯形法计算:
曲线下面积=0.25×(0min血糖+30min血糖)+0.25×(30min血糖+60min血糖)+0.5×(60min血糖+120min血糖)
2.3.胰岛素耐量试验(ITT)
小鼠禁食(不禁水)4h,各组小鼠腹腔注射0.6IU/kg b.w.短效胰岛素。在随后90min内,分别在0min、30min、50min、70min、90min割尾静脉采血,血糖仪测定血糖。
2.4.血脂的测定
小鼠禁食(不禁水)13h,于眼球后静脉丛采血,于4000g离心15min,分离血清,测定TC、TG、LDL-C、HDL-C和FFA。
3.实验结果:
对脂肪乳联合果糖诱导的IGR小鼠进行干预,9周后的糖耐量结果如表1所示。
表1.干预9周后小鼠的糖耐量(n=10)
注:与NC比较,#P<0.05,##P<0.01;与MC比较,*P<0.05,**P<0.01。
由表1可见,模型对照组在饮食诱导9周后表现出联合糖耐量异常,空腹血糖比正常对照组升高28.6%,有极显著差异,其AUC与正常对照组比较存在极显著差异。二甲双胍使小鼠的空腹血糖降低,改善了糖耐量,说明降糖药对小鼠糖调节受损表现出持久有效的预防效果。配方的醇提物高剂量组各点血糖和AUC与模型对照组比较均有显著差异,分别降低24.4%、29.3%、29.5%、19.3%和23.0%,其中剂量组小鼠空腹血糖、30min血糖和AUC降低,与模型对照组比较均有极显著差异。比较灌胃9周后配方提取物对小鼠IGR的干预结果发现:配方的醇提物高剂量改善IGT的同时降低空腹血糖,对小鼠IGR的预防效果持久,呈 量效关系。
配方提取物对IGR小鼠干预第10周进行ITT,结果见表2:
表2.干预10周后小鼠的胰岛素耐量(n=10)
注:与NC比较,##P<0.01;与MC比较,*P<0.05,**P<0.01。
由表2可见,模型对照组小鼠腹腔注射胰岛素后血糖下降,50min时血糖达到最低点,随后血糖开始回升,90min时血糖达到起始血糖的63.6%,起始血糖与90min血糖分别比正常对照组小鼠高52.8%和66.7%,有极显著差异。阳性对照组起始血糖与90min血糖分别比模型对照组下降20.0%和28.6%,有显著差异。配方提取物干预组起始血糖低于模型对照组,且具有显著差异;配方的醇提物高剂量组70min和90min血糖均低于模型对照组(P<0.05),90min血糖仅达到起始血糖的32.1%;配方醇提物中剂量组70min血糖与模型对照组没有差异,可见配方醇提物在提高小鼠胰岛素敏感性的效果上,高剂量优于中剂量,存在量效关系。
配方提取物对IGR小鼠干预第10周进行进行血脂测定,结果见表3。模型对照组饮食诱导10周后,小鼠血清LDL-C、TC和FFA水平显著高于正常对照组。二甲双胍使血清LDL-C和TC含量有升高的趋势。配方醇提物中剂量降低FFA水平,高剂量组降低TC、TG和FFA水平。
表3.干预10周后小鼠的血脂指标(n=10)
注:与NC比较,##P<0.01;与MC比较,*P<0.05,**P<0.01。
经过10周试验,各组小鼠肝脏冷冻切片后进行油红O染色,观察肝组织脂肪沉积情况,结果如图所示。正常对照组肝细胞内仅可见个别大小不一的脂肪空泡,呈阴性。模型对照组小鼠肝细胞内可见弥漫性小的红染脂肪空泡,说明在肝组织中脂肪沉积程度严重,重度脂肪肝。阳性对照组小鼠细胞中可见弥漫性红染脂肪空泡,且脂肪滴较大,说明二甲双胍对肝脂肪变性没有明显的抑制作用。配方醇提取物中剂量组小鼠约30%-40%肝细胞内可见小的红染脂肪空泡,轻度脂肪肝;配方醇提取物高剂量组小鼠的肝组织可见约20%-30%肝细胞内小的红染脂肪空泡,肝细胞脂肪变性。醇提物对抑制脂肪在肝组织中沉积呈量效关系,高剂量优于中剂量。该研究结果表明配方醇提物具有显著减少小鼠肝脏脂肪沉积,预防和减轻脂肪肝形成的功能。
由上所述结果可见,本发明的这种食品组合配方可以起到很好的降低血糖、降低血脂,同时减轻脂肪肝的功效。
Claims (6)
1.一种降血糖、降血脂和改善脂肪肝的食物组合物,其特征在于所述食物组合物中有效成分的原料组成及其重量配比为:葛根3-6份、黄精3-6份、覆盆子3-6份、枸杞2-4份、山楂2-4份、桔梗1-3份、白茅根1-2份。
2.根据权利要求1所述的一种降血糖、降血脂和改善脂肪肝的食物组合物,其特征在于所述食物组合物中有效成分的原料组成及其重量配比为:葛根4份、黄精4份、覆盆子4份、枸杞3份、山楂3份、桔梗2份、白茅根1份。
3.根据权利要求1所述的一种降血糖、降血脂和改善脂肪肝的食物组合物,其特征在于:所述的葛根、黄精和覆盆子按等量加入。
4.根据权利要求1所述的一种降血糖、降血脂和改善脂肪肝的食物组合物,其特征在于:所述的枸杞和山楂按等量加入。
5.根据权利要求1-4任一项所述的一种降血糖、降血脂和改善脂肪肝的食物组合物,其特征在于有效成分的制备工艺包括如下步骤:
步骤A:按重量比精选葛根、黄精、覆盆子、枸杞、山楂、桔梗、白茅根,机械粉碎,过60目筛,获得药材颗粒;
步骤B:加入药材颗粒重量8倍的70%的乙醇,50℃下超声波提取30min,提取三次,过滤,合并提取液;
步骤C:减压回收溶剂,温度低于55℃,得醇提膏状物,进一步干燥为粉状物质。
6.根据权利要求5所述的一种降血糖、降血脂和改善脂肪肝的食物组合物,其特征在于将所述食物组合物制成粉状或颗粒状的营养粉或片剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310469837.6A CN103637179B (zh) | 2013-10-10 | 2013-10-10 | 一种降血糖、降血脂和改善脂肪肝的食物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310469837.6A CN103637179B (zh) | 2013-10-10 | 2013-10-10 | 一种降血糖、降血脂和改善脂肪肝的食物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103637179A true CN103637179A (zh) | 2014-03-19 |
CN103637179B CN103637179B (zh) | 2015-02-18 |
Family
ID=50242586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310469837.6A Expired - Fee Related CN103637179B (zh) | 2013-10-10 | 2013-10-10 | 一种降血糖、降血脂和改善脂肪肝的食物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103637179B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095234A (zh) * | 2014-07-04 | 2014-10-15 | 凯泽(武汉)健康管理有限公司 | 一种调理脂肪肝的功能性食品 |
CN107625129A (zh) * | 2017-09-06 | 2018-01-26 | 如皋市滋生堂生物科技有限公司 | 一种降血糖和降血脂的保健食品及其生产方法 |
CN110506822A (zh) * | 2019-10-10 | 2019-11-29 | 湖北民族大学 | 一种黄精茯苓茶饮品及其制备方法 |
CN114668813A (zh) * | 2022-01-24 | 2022-06-28 | 安徽富韵生物科技有限公司 | 黄精和白刺组合物在调节血糖血脂方面的应用 |
CN114831197A (zh) * | 2022-05-23 | 2022-08-02 | 湖南楚茗茶业有限公司 | 一种复合黑茶及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899446A (zh) * | 2006-07-05 | 2007-01-24 | 吉林农业大学 | 枸杞子片保健品及其制备方法 |
CN101112525A (zh) * | 2006-07-26 | 2008-01-30 | 郁华军 | 一种有补益气血、提神醒脑作用的保健品 |
CN101263901A (zh) * | 2008-04-29 | 2008-09-17 | 刘跃明 | 植物保健酒 |
CN102551140A (zh) * | 2012-01-13 | 2012-07-11 | 唐新秀 | 一种醒酒护肝葛根饮料 |
-
2013
- 2013-10-10 CN CN201310469837.6A patent/CN103637179B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899446A (zh) * | 2006-07-05 | 2007-01-24 | 吉林农业大学 | 枸杞子片保健品及其制备方法 |
CN101112525A (zh) * | 2006-07-26 | 2008-01-30 | 郁华军 | 一种有补益气血、提神醒脑作用的保健品 |
CN101263901A (zh) * | 2008-04-29 | 2008-09-17 | 刘跃明 | 植物保健酒 |
CN102551140A (zh) * | 2012-01-13 | 2012-07-11 | 唐新秀 | 一种醒酒护肝葛根饮料 |
Non-Patent Citations (1)
Title |
---|
王慧芳 等: "药食两用中药降血糖作用研究进展", 《中国煤炭工业医学杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095234A (zh) * | 2014-07-04 | 2014-10-15 | 凯泽(武汉)健康管理有限公司 | 一种调理脂肪肝的功能性食品 |
CN104095234B (zh) * | 2014-07-04 | 2015-10-28 | 凯泽(武汉)健康管理有限公司 | 一种调理脂肪肝的功能性食品 |
CN107625129A (zh) * | 2017-09-06 | 2018-01-26 | 如皋市滋生堂生物科技有限公司 | 一种降血糖和降血脂的保健食品及其生产方法 |
CN110506822A (zh) * | 2019-10-10 | 2019-11-29 | 湖北民族大学 | 一种黄精茯苓茶饮品及其制备方法 |
CN114668813A (zh) * | 2022-01-24 | 2022-06-28 | 安徽富韵生物科技有限公司 | 黄精和白刺组合物在调节血糖血脂方面的应用 |
CN114831197A (zh) * | 2022-05-23 | 2022-08-02 | 湖南楚茗茶业有限公司 | 一种复合黑茶及其制备方法和应用 |
CN114831197B (zh) * | 2022-05-23 | 2023-08-29 | 湖南楚茗茶业有限公司 | 一种复合黑茶及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103637179B (zh) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041118B (zh) | 一种具有降血糖降血脂作用的组合物 | |
CN103285231A (zh) | 一种用于糖尿病辅助治疗的药物组合物及其制法 | |
CN103637179B (zh) | 一种降血糖、降血脂和改善脂肪肝的食物组合物 | |
CN103749822B (zh) | 一种女贞子降压降脂保健茶及其制备方法 | |
CN107822040A (zh) | 一种干姜肉桂保健果冻的制备方法 | |
CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
CN108578544A (zh) | 一种具有降糖作用的中药组合物及其制备方法与应用 | |
CN103749818B (zh) | 一种黄精降糖降脂保健茶及其制备方法 | |
CN103479878A (zh) | 一种调理和治疗糖尿病的药膳茶 | |
CN105124078A (zh) | 一种栀子花降糖降脂保健茶及其制备方法 | |
CN103223111A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
CN104474472B (zh) | 具有降三高作用的苦丁茶含片及其生产方法 | |
CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN108813501A (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
CN104887760A (zh) | 一种灵芝孢子粉酒及其制备方法 | |
CN107625129A (zh) | 一种降血糖和降血脂的保健食品及其生产方法 | |
CN100534461C (zh) | 一种治疗糖尿病及糖耐量低减的药物组合物及制备方法 | |
CN103550505A (zh) | 治疗气阴两虚型糖尿病的中药制剂 | |
CN104606570A (zh) | 一种适宜糖尿病患者服用的消渴代茶饮及制备方法 | |
CN103191297B (zh) | 一种治疗***的中药组合物及其制备方法 | |
CN103599211B (zh) | 一种治疗糖尿病的药物组合物及其制备方法 | |
CN103585434B (zh) | 一种治疗贫血的中药组合物 | |
CN103082298A (zh) | 一种用于辅助降糖的保健食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150218 Termination date: 20161010 |
|
CF01 | Termination of patent right due to non-payment of annual fee |